KINA CRENSHAW: Open Payments
NPI 1851941397 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,978 in 113 payments from 15 companies in 2025. Trend: 2023 $1,458 · 2024 $1,327 · 2025 $1,978
Food & beverage: $1,978
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 28 | $477 |
| E.R. Squibb & Sons, L.L.C. | 15 | $317 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $190 |
| ABBVIE INC. | 27 | $176 |
| Neurocrine BioSciences, Inc. | 7 | $150 |
| Corium, LLC | 7 | $124 |
| Alkermes, Inc. | 5 | $120 |
| Vanda Pharmaceuticals Inc. | 3 | $102 |
| Axsome Therapeutics, Inc. | 5 | $86 |
| PFIZER INC. | 1 | $83 |
Products named: REXULTI, COBENFY, CAPLYTA, VRAYLAR, INGREZZA, Azstarys, ARISTADA, FANAPT.
Industry payments across AL — which companies pay providers there.
